Crescendo Biologics Release: Studies Show Vectra™ DA Multi-Biomarker Test Algorithm More Accurate than Other Established Disease Activity Measures in Identifying Rheumatoid Arthritis Patients at Risk for Joint Damage Progression
11/7/2011 6:31:09 AM
CHICAGO--(BUSINESS WIRE)--Crescendo Bioscience® today announced data indicating that the Company’s multi-biomarker blood test for rheumatoid arthritis (RA) disease activity, Vectra™ DA , may more accurately identify RA patients at risk for progression of joint damage when compared to established disease activity measures. Data demonstrate the Vectra DA algorithm score can identify patients at higher risk for structural damage despite achieving remission by DAS28CRP (the 28-joint disease activity score based on C-reactive protein). Among RA patients in DAS28CRP remission, those who also had a high Vectra DA algorithm score were 2.3 times more likely to have progressive joint destruction during the next year. Moreover, patients in remission as defined by the Vectra DA algorithm score had a lower observed rate of radiographic progression compared to patients in remission by DAS28CRP or by the American College of Rheumatology and the European League Against Rheumatism [ACR/EULAR] Boolean criteria. These and other data are being presented at the American College of Rheumatology and Association of Rheumatology Health Professionals’ Annual Scientific Meeting in Chicago, November 5 – 9, 2011.